Abstract
Ropinirole is a synthesized non-ergotamic dopamine receptor agonist. It has an affinity to D2 and D3 dopamine receptors. It also has a partial affinity to 5-HT1a receptor as pramipexole. The affinity of ropinirole to the D3 receptor is 20 times larger compared to the D2 receptor. It does not have an affinity to the D1 receptor.
This is a preview of subscription content, log in via an institution.
References
Chaudhuri KR, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012;19:105–13.
Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840–4.
Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22:2409–17.
Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of nausea and vomiting in adults using Ropinirole: a systematic review and meta-analysis. Dig Dis Sci. 2018;63:687–93.
Lai KL, Fang Y, Han H, Li Q, Zhang S, Li HY, et al. Orally-dissolving film for sublingual and buccal delivery of ropinirole. Colloids Surf B Biointerfaces. 2018;163:9–18.
Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, STRONG Study Group, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: STRONG study. Mov Disord. 2007;22:1860–5.
Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri H, Ferreira J, Rascol O, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol. 2001;24:181–3.
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174:1930–3.
Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, EASE-PD Adjunct Study Investigators, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108–15.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, 056 Study Group, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21:1844–50.
Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. Sleep duration and “on” time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive Ropinirole prolonged release. Parkinson’s Dis. 2011;2011:354760. https://doi.org/10.4061/2011/354760.
Schrag A, Keens J, Warner J, Ropinirole Study Group. Ropinirole for the treatment of tremor in early Parkinson’s disease. Eur J Neurol. 2002;9:253–7.
Singh ND, Banga AK. Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. J Drug Target. 2013;21:354–66.
Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24:2883–95.
Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26:1259–65.
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, REAL-PET Study Group, et al. Slower progression of Parkinson’s disease with Ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.
Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 2013;19:1022–6.
Zhou CQ, Lou JH, Zhang YP, Zhong L, Chen YL, Lu FJ, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014;20:368–76.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Konaka, K., Mochizuki, H. (2020). Ropinirole in the Treatment of Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_235-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_235-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine